A proposed provision in the historic US cannabis legalization under consideration would set an unnecessarily low level of trace amounts of THC in food products based on hemp blossoms, resulting in “the elimination of the vast majority of the hemp extract and CBD industry,” a trade group warned .
In a letter sent to major sponsors of the Cannabis Management and Opportunity Act (CAOA), which was filed in the Senate last month, the US Hemp Roundtable (USHR), a Kentucky-based trade association, criticized the THC provision in the bill, which sets a 1 milligram limit of Total THC per 100g on a dry weight basis, which translates to 0.001% of the total standard THC.
The CAOA, considered the most comprehensive of several cannabis bills currently in the US Congress, is not expected to become law any time soon, but it does serve as the center of gravity for the marijuana and cannabis policy debate.
The bill would recognize the legalization of cannabis by states, decriminalize the regulation and taxation of corporations, and provide provisions relating to justice, immigration, and enforcement; small business management; Public Health; education infrastructure; the work; ancient warrior; banking and housing; and community development.
The US Food and Drug Administration (FDA) will regulate cannabis products through a new Center for Cannabis Products, under the terms of the proposed law.
“This is an arbitrary and unrealistic standard,” the USHR said of the proposed THC limit for hemp-based products. “There is no qualified full spectrum or broad spectrum hemp extract, and it is likely that most CBD isolates will be challenged for compliance, given the limitations of current testing technology.
“In effect, such a limit would delegate most, if not all, common, non-intoxicating CBD and cannabis extract products to the adult cannabis market,” the group said, urging sponsors of the bill to reconsider what it called “the misleading standard of intoxication.” Which is “uniquely and unprecedentedly stressful”.
Delta-8 . must be regulated
In the letter sent to Senator Ron Wyden of Oregon, Senator Cory Booker of New Jersey and Senator Chuck Schumer of New York, the primary sponsors of the CAOA, the USHR called for expanded protections for all non-intoxicating cannabinoids including CBD and other cannabinoids, and the legalization of Selling CBD and other hemp extracts as ingredients to foods and beverages, diluting who can conduct safety assessments.
Despite its strong defense of CBD, the USHR said it supports CAOA’s efforts to regulate psychoactive cannabis products, such as delta-8 THC, which is derived from hemp-based CBD. Separate regulatory pathways should be established for non-intoxicating cannabis and intoxicating cannabis products, the USHR recommended.
The CAOA should be changed to create a more comprehensive rule-making process to define the limits of the daily CBD service inviting stakeholders, the USHR has also urged.
Suggest the staff
In addition to the permissible levels of THC for consumer products, the USHR said other provisions in current CAOA language could undermine the industry, and urged the creation of a task force to establish regulations for daily serving limits for CBD, and to consider the desirability of the current delta-9 THC limit for cannabis plants of 0.3 %, and processing of other potentially intoxicating cannabis derivatives.
The task force will include representatives from the US Food and Drug Administration (FDA), the National Institute on Drug Abuse of the National Institutes of Health, cannabis growers, manufacturers, processors, distributors and testing laboratories.
The group will report findings and make recommendations within 120 days after it is formed, as recommended by the USHR. The FDA and other federal agencies will have 90 days to begin the rule-making process to implement the task force’s recommendations.
Reforms are moving slowly
Observers said incremental cannabis reforms are expected in the near future, especially if Democrats lose the Senate in the 2022 midterm elections. Banking problems can be resolved, for example, through separate legislation, the Safe Banking Services Act (SAFE), which It would eventually allow financial institutions to service cannabis companies without fear of reprisals.
While CAA sponsors have said they will not support the SAFE banking law in the absence of broader criminal reforms, the policy that provides basic financial services to cannabis operators has bipartisan support in Congress.
The Hemp Roundable US Tour is led by Pete Mitchum, President, a lobbying member who also serves as the Cronos Group’s Senior Director of Governmental Affairs, Ontario, Canada. The following companies and organizations are on the USHR Board of Directors, according to the group’s website: Ananda Hemp (Kentucky), Balanced Health Botanicals (Colorado), Canopy Growth Corporation (Ontario, Canada), CBD American Shaman (Kansas), Cultured CBD (Minnesota) , Coralif (Massachusetts), Garden of Life (Florida), GVB Biopharma (Nevada), Hemp Industries Association, Just Brands (Netherlands), Koi CBD LLC (California), Medterra CBD (California), Recess (New York), Red Mesa Science & Refining (Utah), SC Labs (California), Turning Point Brands (Kentucky), US Cannabis Authority, Verge Agritech (UK), and Zilis (Texas).